Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Disappoints Street, But Stays Its Course

This article was originally published in The Pink Sheet Daily

Executive Summary

Eli Lilly & Co. failed to meet the Street’s expectations on Jan. 5 when it held a guidance call with analysts, largely due to the rapid erosion of its newly genericized antipsychotic Zyprexa.

You may also be interested in...

Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation

Lilly Prepares For Zyprexa Expiration; Increases R&D Spend

Lilly's earnings are in line with analyst expectations, but higher costs cut into profits as the company prepares for a revenue decline.

No Big Surprises From Lilly: Management Sticks To Its Guns On Strategy

With the loss of Zyprexa just months away, Eli Lilly management sought to reassure investors its strategy of focusing on its internal pipeline and core growth areas will pay off post-2014.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts